TR201907261T4 - DKK-1 antikorları. - Google Patents

DKK-1 antikorları. Download PDF

Info

Publication number
TR201907261T4
TR201907261T4 TR2019/07261T TR201907261T TR201907261T4 TR 201907261 T4 TR201907261 T4 TR 201907261T4 TR 2019/07261 T TR2019/07261 T TR 2019/07261T TR 201907261 T TR201907261 T TR 201907261T TR 201907261 T4 TR201907261 T4 TR 201907261T4
Authority
TR
Turkey
Prior art keywords
dkk
antibodies
human
antigen
bind
Prior art date
Application number
TR2019/07261T
Other languages
English (en)
Inventor
Chedid Marcio
James Darling Ryan
Jeanette Galvin Rachelle
Anne Swanson Barbara
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TR201907261T4 publication Critical patent/TR201907261T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Buluş beşeri DKK-1'e bağlanan ve aktivitesini inhibe eden ve patogeneze DKK-1'in aracılık ettiği hastalıkların tedavisinde etkili olan, beşeri tasarlanmış antikorlar ve bunların antijen bağlayıcı fragmanlarını sunmaktadır.
TR2019/07261T 2009-04-10 2010-04-06 DKK-1 antikorları. TR201907261T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10

Publications (1)

Publication Number Publication Date
TR201907261T4 true TR201907261T4 (tr) 2019-06-21

Family

ID=42199718

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07261T TR201907261T4 (tr) 2009-04-10 2010-04-06 DKK-1 antikorları.

Country Status (30)

Country Link
US (1) US8148498B2 (tr)
EP (3) EP2417158B9 (tr)
JP (1) JP5759977B2 (tr)
KR (3) KR20110124364A (tr)
CN (1) CN102388065B (tr)
AR (1) AR075989A1 (tr)
AU (1) AU2010234611B2 (tr)
BR (1) BRPI1014157B1 (tr)
CA (1) CA2758252C (tr)
CY (3) CY1119399T1 (tr)
DK (3) DK3514173T3 (tr)
EA (1) EA021401B1 (tr)
ES (3) ES2887176T3 (tr)
HR (3) HRP20171400T1 (tr)
HU (3) HUE055376T2 (tr)
IL (1) IL214845A (tr)
LT (3) LT2417158T (tr)
ME (2) ME02798B (tr)
MX (1) MX2011010707A (tr)
NZ (1) NZ595011A (tr)
PL (3) PL2417158T3 (tr)
PT (3) PT3514173T (tr)
RS (3) RS62214B1 (tr)
SG (1) SG175244A1 (tr)
SI (3) SI2417158T1 (tr)
TR (1) TR201907261T4 (tr)
TW (1) TWI546079B (tr)
UA (1) UA103916C2 (tr)
WO (1) WO2010117980A1 (tr)
ZA (1) ZA201107256B (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666584A (zh) 2009-05-12 2012-09-12 辉瑞公司 封闭性抗dkk-1抗体及其用途
DK2928923T3 (da) 2012-12-10 2020-02-17 Biogen Ma Inc Antistoffer mod dendritisk celle-antigen 2 fra blod og anvendelser deraf
AU2016263030A1 (en) * 2015-05-18 2017-10-12 Eli Lilly And Company Anti-Dkk-1-anti-RANKL bispecific antibody compounds
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
JP7374765B2 (ja) * 2016-10-26 2023-11-07 リープ セラピューティクス，インコーポレイテッド 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用
MX2021000306A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4.
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
WO2021055789A1 (en) 2019-09-19 2021-03-25 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
CN114929275A (zh) 2019-11-22 2022-08-19 飞跃治疗公司 使用dkk-1抑制剂治疗癌症的方法
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
CA3206789A1 (en) * 2021-02-05 2022-08-11 Gregory A. Demopulos Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
WO2024015463A1 (en) 2022-07-12 2024-01-18 Leap Therapeutics, Inc. Combination therapy
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2285768T5 (es) 1997-04-16 2011-12-22 Millennium Pharmaceuticals, Inc. Proteínas crsp (proteínas segregadas ricas en cisteína), moléculas de ácido nucleico que codifican para las mismas y uso.
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
EP1490386B1 (en) 1998-03-10 2008-08-13 Genentech, Inc. Novel polypeptide and nucleic acids encoding the same
EP1572987A4 (en) 2000-02-03 2005-11-30 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
JP2005512508A (ja) 2001-05-17 2005-05-12 ゲノム　セラピューティックス　コーポレーション Ｄｋｋ媒介性相互作用を変調する試薬および方法
EP1461448A2 (en) 2001-11-07 2004-09-29 The Board Of Trustees Of The University Of Arkansas Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
BRPI0411020A (pt) 2003-06-06 2006-07-18 Wyeth Corp perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição
EP1786837B1 (en) * 2004-08-04 2013-05-01 Amgen Inc., Antibodies to dkk-1
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
JP2010517570A (ja) * 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ｄｋｋ−１に特異的な抗体
BRPI1014535A2 (pt) * 2009-05-07 2016-04-05 Novatis Ag composições e métodos de uso para moléculas de ligação a dickkopf-1 ou dickkopf-4 ou ambas

Also Published As

Publication number Publication date
HRP20190643T1 (hr) 2019-05-31
DK2930184T3 (da) 2019-05-13
PL2417158T3 (pl) 2017-12-29
PL3514173T3 (pl) 2022-01-17
ES2644244T3 (es) 2017-11-28
HRP20171400T1 (hr) 2017-11-03
HRP20211343T1 (hr) 2021-11-26
SI3514173T1 (sl) 2021-09-30
TW201100101A (en) 2011-01-01
LT2417158T (lt) 2017-10-10
EP2417158A1 (en) 2012-02-15
CA2758252A1 (en) 2010-10-14
ES2887176T3 (es) 2021-12-22
RS58612B1 (sr) 2019-05-31
EP2417158B9 (en) 2017-12-06
AU2010234611B2 (en) 2013-02-07
US20100260754A1 (en) 2010-10-14
CY1124412T1 (el) 2022-07-22
SI2417158T1 (sl) 2017-10-30
PT2930184T (pt) 2019-06-17
CN102388065B (zh) 2014-09-03
LT2930184T (lt) 2019-05-10
AR075989A1 (es) 2011-05-11
BRPI1014157A2 (pt) 2020-09-29
KR20110124364A (ko) 2011-11-16
RS62214B1 (sr) 2021-09-30
HUE055376T2 (hu) 2021-11-29
EP3514173B8 (en) 2021-08-04
HUE034625T2 (en) 2018-02-28
EP3514173B1 (en) 2021-06-23
AU2010234611A1 (en) 2011-10-20
BRPI1014157B1 (pt) 2022-01-18
MX2011010707A (es) 2012-02-28
CN102388065A (zh) 2012-03-21
IL214845A (en) 2016-06-30
PT2417158T (pt) 2017-10-23
CY1119399T1 (el) 2018-02-14
JP5759977B2 (ja) 2015-08-05
EA021401B1 (ru) 2015-06-30
EP3514173A1 (en) 2019-07-24
PL2930184T3 (pl) 2019-10-31
EP2930184B1 (en) 2019-03-27
CA2758252C (en) 2015-02-24
ME03378B (me) 2020-01-20
NZ595011A (en) 2013-05-31
SG175244A1 (en) 2011-12-29
ES2728911T3 (es) 2019-10-29
DK2417158T4 (da) 2018-01-29
DK3514173T3 (da) 2021-08-02
WO2010117980A1 (en) 2010-10-14
EA201171237A1 (ru) 2012-04-30
ZA201107256B (en) 2013-03-27
UA103916C2 (en) 2013-12-10
KR101461362B1 (ko) 2014-11-13
TWI546079B (zh) 2016-08-21
KR20140090273A (ko) 2014-07-16
JP2012523417A (ja) 2012-10-04
EP2930184A1 (en) 2015-10-14
EP2417158B1 (en) 2017-08-02
IL214845A0 (en) 2011-11-30
LT3514173T (lt) 2021-09-10
CY1121637T1 (el) 2020-07-31
KR20140033523A (ko) 2014-03-18
US8148498B2 (en) 2012-04-03
PT3514173T (pt) 2021-08-16
RS56505B1 (sr) 2018-02-28
SI2930184T1 (sl) 2019-06-28
DK2417158T3 (en) 2017-10-16
HUE043904T2 (hu) 2019-09-30
ME02798B (me) 2018-01-20

Similar Documents

Publication Publication Date Title
TR201907261T4 (tr) DKK-1 antikorları.
UA109658C2 (xx) Антитіло проти cgrp
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
JO3097B1 (ar) الأجسام المضادة c-Met
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
EA201590247A1 (ru) Антитела к siglec-15
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201370081A1 (ru) Антитела к cd48 и их применение
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
WO2012021786A3 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
GB201109238D0 (en) Antibodies